Ask Warren

SK biopharmaceuticals

326030 · KOSPI · ₩326030 · SK바이오팜

₩77,800▲ ₩2,600 (3.46%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −32.11%
Market cap
₩6.1T
Enterprise value
₩5.7T
P/E
15.2×
P/B
6.0×
Dividend yield
0.0%
ROE
39.2%
Net margin
46.6%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−46.0% from the high

₩67,800Today: ₩74,500 – ₩78,300₩144,100

Returns

  • 1W+3.9%
  • 1M+3.9%
  • 3M+0.3%
  • 6M−22.1%
  • YTD−37.6%
  • 1Y−32.1%
Volume today
207,734
1.9× the 20-day average
Traded today
₩16B
Listed shares
78,313,250
EPS (12 months)
₩5,120
Earnings yield 6.6%
SellBuy
AI research · InitiationSK biopharmaceuticals: Profits Have Climbed Since 2023 While the Share Price Sits Near Its 52-Week LowThe filed financials show a strong improvement in revenue, margins and cash generation, with low leverage and a trailing P/E of 13.9 that is below its peers and its 2025 year-end level.Read the full report →

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

53Normal
  • BuzzNormalBuzz 53: heavy trading.
  • MomentumFlat2.1% over the last month; the price is above its 20-day average.
  • News impactSome3 news items and filings in two weeks; 0 rated high impact, 1 medium.

Signals describe activity, not recommendations. Not financial advice.

Leveraged ETF flows

Estimated leveraged-ETF rebalance on Oct 29: sell ₩194M at the close (2.4% of 20-day average trading value)

Sep 30Last 20 trading days (% of average trading value)Oct 29

On its 12 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 7.3% of trading value and pointed the same way 7 of 12 times.

  • -2× KODEX 200 Futures Inverse 2X −₩138M
  • 2× KODEX Leverage −₩17M
  • 2× TIGER 200IT Leverage −₩9.4M
  • -1× KODEX Inverse −₩8.3M
  • 2× TIGER Leverage −₩6.5M

Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.

Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.

Estimate based on ETF size and daily moves; actual trades may differ.

ETFs holding this

All ETFs →

Held by 32 funds.

Estimated from the funds' index or underlying stock.

Futures and options

All stock futures →

Futures (2026-11): 77,500

Basis −0.39% · implied rate −10.1%

Open interest 7,031 contracts

Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.

SK biopharmaceuticals stock overview

SK biopharmaceuticals (SK바이오팜, KRX: 326030) is listed on KOSPI, in the Biotech & Pharma sector. SK Biopharmaceuticals develops innovative drugs, focusing on central nervous system diseases, especially epilepsy, and has expanded into radiopharmaceutical and targeted protein degradation therapies for oncology. Its shares closed at ₩77,800 on Oct 29, 2026, up 3.46% on the day, giving it a market value of ₩6.1T.

Key facts

Market cap
₩6.1T
Sector
Biotech & Pharma
Latest price change
+3.46%
As of
Oct 29, 2026
Main business
SK Biopharmaceuticals develops innovative drugs, focusing on central nervous system diseases, especially epilepsy, and has expanded into radiopharmaceutical and targeted protein degradation therapies for oncology.

Quick answers about SK biopharmaceuticals

What does SK biopharmaceuticals do?
SK Biopharmaceuticals develops innovative drugs, focusing on central nervous system diseases, especially epilepsy, and has expanded into radiopharmaceutical and targeted protein degradation therapies for oncology. Its main product is the epilepsy treatment cenobamate, sold directly in the United States as XCOPRI and in Europe as ONTOZRY, and it has licensed cenobamate to partners covering regions including China, Japan, Korea, Canada, Latin America and the Middle East and North Africa. Its other licensed product is solriamfetol, a sleep disorder treatment marketed in the United States as SUNOSI.
What is the market cap of SK biopharmaceuticals?
The market capitalisation of SK biopharmaceuticals was ₩6.1T at the close on Oct 29, 2026.
Who are the largest shareholders of SK biopharmaceuticals?
According to the latest official filings, the largest reported holders are SK (50.14%, as of Mar 31, 2026); National Pension Service (6.00%, as of Apr 1, 2026); iShares MSCI South Korea ETF (0.77%, as of May 31, 2026).
When is the next earnings report from SK biopharmaceuticals?
Korean companies rarely announce results dates in advance. Based on when SK biopharmaceuticals filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Does the National Pension Service own SK biopharmaceuticals?
Yes. The National Pension Service held 6.00% of SK biopharmaceuticals shares as of Apr 1, 2026.

Company profile

SK Biopharmaceuticals develops innovative drugs, focusing on central nervous system diseases, especially epilepsy, and has expanded into radiopharmaceutical and targeted protein degradation therapies for oncology. Its main product is the epilepsy treatment cenobamate, sold directly in the United States as XCOPRI and in Europe as ONTOZRY, and it has licensed cenobamate to partners covering regions including China, Japan, Korea, Canada, Latin America and the Middle East and North Africa. Its other licensed product is solriamfetol, a sleep disorder treatment marketed in the United States as SUNOSI.

Written by AI from the company's latest annual report.

Korean name
SK바이오팜
Sector
Biotech & Pharma
Themes
Biotech (new drugs)
Business group
SK
CEO
이동훈
Founded
Apr 2011
Listed
Jul 2020
Listed shares
78,313,250
Fiscal year ends
Month 12
Website
www.skbp.com

Similar companies

Recent news

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: SK biopharmaceuticals / SK바이오팜 / 326030 / KRX:326030

Source: KRX statistical information